ALK awaits crucial adrenaline data in 2021 and plans to submit FDA application in less than three years

Allergy company ALK will receive crucial trial data from partner Windgap which is working on a next-generation adrenaline pen which ALK has the rights to. Meanwhile, ALK is developing its own adrenaline pen based on experiences with Jext. The firm is confident it will be submitting a registration application to the US FDA before 2024.
Photo: Gregers Tycho/Ritzau/Ritzau Scanpix
Photo: Gregers Tycho/Ritzau/Ritzau Scanpix
BY ALBERT RØNNING_ANDERSSON, TRANSLATED BY NIELSINE NIELSEN

ALK's allergy specialists want more than a dominant position in the US market for tablet treatments for patients with allergies.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading